| 2000 | ||
|---|---|---|
| Sep. | Founded in San Diego, California, USA | |
| Dec. | First Series A Preferred Stock Issued to Tanabe Seiyaku Co., Ltd. |
| 2001 | ||
|---|---|---|
| Aug. | Second Series A Preferred Stock Issued to Tanabe Seiyaku Co., Ltd. |
| 2002 | ||
|---|---|---|
| Mar. | Licensed anti-inflammatory agent MN-001 from Kyorin Pharmaceutical Co., Ltd. |
| 2004 | ||
|---|---|---|
| Apr. | Series B Preferred Stock Issuance | |
| Jun. | Series C Preferred Stock Issuance | |
| Oct. | Licensed the rights for the development of the anti-inflammatory drug ibudilast for relapsing-remitting multiple sclerosis from Kyorin Pharmaceutical Co., Ltd. |
| 2005 | ||
|---|---|---|
| Feb. | Initial public offering and new common stock issuance (Osaka Securities Exchange Hercules Foreign Section) |
| 2006 | ||
|---|---|---|
| Dec. | Listed on the U.S. NASDAQ, established a subsidiary in the U.K. |
| 2007 | ||
|---|---|---|
| Jan. | Japanese subsidiary established |
| 2009 | ||
|---|---|---|
| Dec. | Acquired U.S. company Avigen, obtaining development rights for AV411 (ibudilast) and others |
| 2019 | ||
|---|---|---|
| Mar. | Establishment of a German subsidiary |
| 2022 | ||
|---|---|---|
| Apr. | Transition to the Tokyo Stock Exchange Standard Market |
| 2024 | ||
|---|---|---|
| Jun. | Establishment of a Canadian subsidiary |
| 2000 | |
|---|---|
| Sep. | Founded in San Diego, California, USA |
| Dec. | First Series A Preferred Stock Issued to Tanabe Seiyaku Co., Ltd. |
| 2001 | |
|---|---|
| Aug. | Second Series A Preferred Stock Issued to Tanabe Seiyaku Co., Ltd. |
| 2002 | |
|---|---|
| Mar. | Licensed anti-inflammatory agent MN-001 from Kyorin Pharmaceutical Co., Ltd. |
| 2004 | |
|---|---|
| Apr. | Series B Preferred Stock Issuance |
| Jun. | Series C Preferred Stock Issuance |
| Oct. | Licensed the rights for the development of the anti-inflammatory drug ibudilast for relapsing-remitting multiple sclerosis from Kyorin Pharmaceutical Co., Ltd. |
| 2005 | |
|---|---|
| Feb. | Initial public offering and new common stock issuance (Osaka Securities Exchange Hercules Foreign Section) |
| 2006 | |
|---|---|
| Dec. | Listed on the U.S. NASDAQ, established a subsidiary in the U.K. |
| 2007 | |
|---|---|
| Jan. | Japanese subsidiary established |
| 2009 | |
|---|---|
| Dec. | Acquired U.S. company Avigen, obtaining development rights for AV411 (ibudilast) and others |
| 2019 | |
|---|---|
| Mar. | Establishment of a German subsidiary |
| 2022 | ||
|---|---|---|
| Apr. | Transition to the Tokyo Stock Exchange Standard Market |
| 2024 | ||
|---|---|---|
| Jun. | Establishment of a Canadian subsidiary |